Gilliland Jeter Wealth Management LLC Makes New Investment in Edwards Lifesciences Co. (NYSE:EW)

Gilliland Jeter Wealth Management LLC bought a new stake in Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 5,725 shares of the medical research company’s stock, valued at approximately $437,000.

A number of other institutional investors also recently modified their holdings of the business. Headlands Technologies LLC boosted its position in shares of Edwards Lifesciences by 115.4% in the fourth quarter. Headlands Technologies LLC now owns 5,362 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 2,873 shares during the period. Callan Capital LLC bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $2,116,000. Bahl & Gaynor Inc. bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $404,000. Bank Julius Baer & Co. Ltd Zurich boosted its position in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 794,611 shares of the medical research company’s stock valued at $60,589,000 after acquiring an additional 2,000 shares during the period. Finally, Sandhill Capital Partners LLC boosted its position in shares of Edwards Lifesciences by 3.7% in the fourth quarter. Sandhill Capital Partners LLC now owns 24,972 shares of the medical research company’s stock valued at $1,904,000 after acquiring an additional 900 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 1.8 %

Shares of EW traded down $1.58 during trading hours on Friday, reaching $86.43. The stock had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The firm has a 50-day simple moving average of $90.28 and a 200 day simple moving average of $78.85. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a market capitalization of $52.02 billion, a price-to-earnings ratio of 37.25, a P/E/G ratio of 4.36 and a beta of 1.05. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.34% and a net margin of 23.01%. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Equities research analysts predict that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Evercore ISI dropped their price target on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research note on Friday. Wells Fargo & Company boosted their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday. Piper Sandler boosted their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research note on Friday. Mizuho boosted their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Finally, OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $93.33.

Insider Activity

In other news, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now owns 34,814 shares in the company, valued at approximately $2,980,774.68. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the transaction, the vice president now directly owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.